Vyne Therapeutics Inc
NASDAQ:VYNE
Vyne Therapeutics Inc
VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. The company is headquartered in Bridgewater, New Jersey and currently employs 28 full-time employees. The company went IPO on 2018-01-25. The firm is engaged in developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions and rare skin diseases with high unmet medical need. The Company’s proprietary pipeline FMX114, which is a potential treatment of mild-to-moderate atopic dermatitis in patients 12 years of age and older, and access to a library of bromodomain and extra-terminal (BET) domain inhibitors in both topical and oral forms for the potential treatment of major immuno-inflammatory conditions and rare skin diseases.
VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. The company is headquartered in Bridgewater, New Jersey and currently employs 28 full-time employees. The company went IPO on 2018-01-25. The firm is engaged in developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions and rare skin diseases with high unmet medical need. The Company’s proprietary pipeline FMX114, which is a potential treatment of mild-to-moderate atopic dermatitis in patients 12 years of age and older, and access to a library of bromodomain and extra-terminal (BET) domain inhibitors in both topical and oral forms for the potential treatment of major immuno-inflammatory conditions and rare skin diseases.
Strategic Shift: VYNE reported continued progress on its transformation toward immuno-inflammatory disease therapies, highlighted by rapid development of its BET inhibitor platform.
Pipeline Progress: The company aims to advance VYN201 (topical BET inhibitor) and VYN202 (oral BET inhibitor) into clinical trials in 2022, with early preclinical data showing strong anti-inflammatory potential for VYN201.
Clinical Milestone: Enrollment began for the Phase 1b/2a trial of FMX114 for atopic dermatitis, with topline results expected in early Q1 2022.
Cost Reduction: Adjusted operating expenses fell $1.9 million from the previous quarter, with further reductions expected in Q4.
Financial Position: Cash stood at approximately $53 million as of September 30, 2021, expected to fund operations through Q2 2022.
Divestiture Update: The planned sale of the topical minocycline franchise (AMZEEQ, ZILXI, FCD105) is underway, with strong market interest reported.
